Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome (LEAP)
Status: Recruiting
Location: See all (8) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The goal of this observational study is to evaluate the long-term safety and clinical outcomes of Livmarli prescribed to patients with Alagille Syndrome (ALGS).
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• A clinically and/or genetically confirmed ALGS diagnosis
• Participant prescribed Livmarli
Locations
United States
California
Children's Hospital Los Angeles CHLA
RECRUITING
Los Angeles
Colorado
Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics and the Digestive Health Institute, Children's Hospital of Colorado and University of Colorado
RECRUITING
Aurora
Georgia
Children's Healthcare of Atlanta - Emory University School of Medicine
RECRUITING
Atlanta
Missouri
Children's Mercy Kansas City, Department of Gastroenterology, Section of Hepatology
RECRUITING
Kansas City
Oregon
Oregon Health and Science University, Division of Pediatric Gastroenterology, Department of Pediatrics
RECRUITING
Portland
Pennsylvania
Children's Hospital of Philadelphia
RECRUITING
Philadelphia
Children Hospital of Pittsburgh
RECRUITING
Pittsburgh
Utah
University of Utah, Division of Pediatric Gastroenterology, Hepatology and Nutrition
RECRUITING
Salt Lake City
Contact Information
Primary
Clinical Trials Mirum
Clinical Trials <clinicaltrials@mirumpharma.com>;
+16506674085
Time Frame
Start Date: 2023-09-21
Estimated Completion Date: 2028-09-20
Participants
Target number of participants: 50
Treatments
Alagille syndrome (ALGS)
* A clinically and/or genetically confirmed ALGS diagnosis~* Participant prescribed Livmarli
Related Therapeutic Areas
Sponsors
Leads: Mirum Pharmaceuticals, Inc.